Have a personal or library account? Click to login
The role of toll-like receptor 9 (TLR9) in Epstein-Barr virus-associated gastric cancer Cover

The role of toll-like receptor 9 (TLR9) in Epstein-Barr virus-associated gastric cancer

Open Access
|Jun 2020

Abstract

Epstein-Barr virus-associated gastric carcinoma (EBVaGC) is the most common malignancy caused by EBV infection. Toll-like receptors (TLRs) as major components of innate immune system are crucial in the development of inflammatory processes and carcinogenesis. The aim of our study was to evaluate tissue and serum level of TLR9 in EBV-positive and EBV-negative gastric cancer patients. The study involved 30 EBV(+) and 30 EBV(-) patients. EBV DNA was detected in fresh frozen tumor tissue. In serum samples TLR9 level, transforming growth factor β (TGFβ), interleukin 10 (IL-10) and antibodies against EBV were detected using ELISA tests. TLR9 level was also measured in homogenate of tumour tissue. TLR9 level was statistically lower in EBV(+) patients both in serum and tissue, with statistically higher level in tissue than in serum. Lower level of TLR9 was accompanied by higher level of Epstein-Barr virus capsid antigen (EBVCA), Epstein-Barr virus nuclear antigen (EBNA) and early antigen (EA). A lower level of TLR9 was detected in patients with poorly differentiated cancer (G3) and greater lymph nodes involvement (N3-N4). Lower level of TLR9 in patients with EA may point to TLR9 role in reactivation of EBV infection.

DOI: https://doi.org/10.2478/cipms-2020-0020 | Journal eISSN: 2300-6676 | Journal ISSN: 2084-980X
Language: English
Page range: 106 - 111
Submitted on: Jan 10, 2020
|
Accepted on: Feb 20, 2020
|
Published on: Jun 25, 2020
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2020 Anna Dworzanska, Malgorzata Strycharz-Dudziak, Jakub Dworzanski, Agnieszka Stec, Barbara Rajtar, Bartlomiej Drop, Malgorzata Polz-Dacewicz, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.